Monoclonal Antibody Therapeutics Market

7500+ companies worldwide approach us every year for their revenue growth initiatives
Global top 2000 strategist rely on us for their growth strategies.
80% of fortune 2000 companies rely on our research to identify new revenue sources.
30000 High Growth Opportunities
95% renewal rate
KNOW MORE
  1. HOME
  2. Top Market Reports
  3. Monoclonal Antibody Therapeutics Market

Monoclonal Antibody Therapeutics Market / mABs Therapeutics Market Size by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029

FREE BROCHURE FREE SAMPLE REPORT
Report Code: PH 8974 Mar, 2024, by marketsandmarkets.com

The size of global monoclonal antibody therapeutics market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

Driving factors of the market, including clinical trials, encompass increasing prevalence of complex diseases, advancements in biotechnology facilitating targeted treatments, regulatory support expediting approval processes, and robust investments in research and development. Clinical trials play a pivotal role in validating efficacy, safety, and commercial viability, driving market growth.

Monoclonal Antibody Therapeutics Market- Global Forecast to 2029

Monoclonal Antibody (mABs) Therapeutics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Attractive Opportunities in the Monoclonal Antibody Therapeutics Market

Monoclonal Antibody (mABs) Therapeutics Market

Global Monoclonal Antibody Therapeutics Market Dynamics

DRIVER: Advancements in Biotechnology and Genetic Engineering

Advancements in biotechnology and genetic engineering are pivotal in propelling the growth of the market. Techniques such as recombinant DNA technology enable the production of monoclonal antibodies with enhanced efficacy, reduced immunogenicity, and improved pharmacokinetics. Moreover, innovations in cell culture systems and protein engineering facilitate the development of novel therapeutic candidates, expanding the treatment landscape for various diseases, including cancer, autoimmune disorders, and infectious diseases, driving market expansion and innovation.

RESTRAINT: Cost Burden on patients

The cost burden on patients presents a significant restraint to the growth of the market. These treatments often come with high price tags due to complex manufacturing processes and extensive research and development costs. As a result, accessibility and affordability issues arise, limiting patient access and hindering market expansion. Efforts to address pricing concerns, such as the introduction of biosimilars and reimbursement strategies, are crucial to mitigate this barrier and promote market growth.

OPPORTUNITY: Expansion into new therapeutic areas

Expansion into new therapeutic areas is creating growth opportunities for the market. With ongoing research and development efforts, monoclonal antibodies are being explored for a wider range of diseases beyond their traditional applications, including neurological disorders, infectious diseases, and rare genetic conditions. This diversification of indications broadens the market scope, attracting investment and fostering innovation, ultimately driving growth and advancing the role of monoclonal antibodies in modern healthcare.

CHALLENGE: Data interpretation challenges

The high cost of monoclonal antibody (mAb) development poses significant challenges for the growth of the market. From research and preclinical studies to clinical trials and manufacturing, the process entails substantial expenses. These costs are often passed on to patients, limiting accessibility and affordability. Addressing this challenge requires innovative financing models, collaborative efforts among stakeholders, and optimization of manufacturing processes to reduce production expenses and improve market sustainability.

Global Monoclonal antibody therapeutics Industry Ecosystem Analysis

The monoclonal antibody therapeutics market ecosystem comprises production method, source, therapy area, route of administration, regulatory authorities, and end users, such as hospitals, long-term care facilities and other end users.

Monoclonal Antibody (mABs) Therapeutics Market Ecosystem

In-Vitro segment held a dominant share in production method segment in the monoclonal antibody therapeutics industry

On the basis production method, the monoclonal antibody therapeutics market is segmented into in-vitro and in-vivo. In 2023, in-vitro segment accounted for the largest share of the global market. Driving factors of the in-vitro production method monoclonal antibody-therapeutics market include scalability, cost-effectiveness, and reduced batch-to-batch variability.

Human segment held a dominant share in source segment in the monoclonal antibody therapeutics industry

On the basis of sources, the monoclonal antibody therapeutics market is segmented into human, humanized, chimeric and other sources. In 2023, human source segment dominated market and humanized segment is likely to grow at significant CAGR during the forecast period of 2024-2029. Driving factors of the human source monoclonal antibody-therapeutics market include enhanced efficacy, reduced immunogenicity, and improved safety profiles. Examples: Monoclonal antibodies derived from humanized or fully human sources like adalimumab (Humira) and pembrolizumab (Keytruda).

Oncology is likely to grow at significant CAGR in the monoclonal antibody therapeutics industry

On the basis therapy area, the monoclonal antibody therapeutics market is segmented into autoimmune & inflammatory disorders, oncology, hematology, opthalmology and other therapy areas. Autoimmune & inflammatory diseases dominated the global market in 2023. Driving factors of onocology as a therapy area in the market include high incidence rates, increasing awareness, and demand for targeted treatments.

The hospitals segment of the monoclonal antibody therapeutics industry is expected to register fastest growth during the forecast period.

Based on the hospitals, monoclonal antibody therapeutics market has been segmented into hospitals, long-term care facilities, and other end users. In 2023, the hospitals segment accounted for the largest share in global market. Driving factors of the hospitals end user segment in the market include advanced infrastructure, access to specialized care, and higher patient volumes.

North America accounted for the largest share of the monoclonal antibody therapeutics industry in 2023

Geographically, the monoclonal antibody therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America's dominance in the global market is driven by robust research and development infrastructure, high healthcare expenditure, supportive regulatory frameworks like the FDA, and a large patient pool. Major companies like Genentech, Amgen, and Pfizer contribute to this dominance.

Monoclonal Antibody (mABs) Therapeutics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key players in the global monoclonal antibody therapeutics market include F. Hoffmann-La Roche Ltd (Switzerland), Abbvie Inc. (US), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Bristol Myers Squibb Company (US), AstraZeneca (UK), Sanofi (France), Novartis AG (Switzerland), Amgen Inc. (US), Takeda Pharmaceutical Company Limited (Japan), GSK plc. (UK), Eli Lilly and Company (US), Regeneron Pharmaceuticals Inc. (US), Biogen (US), UCB S.A. (Belgium), Boehringer Ingelheim International GmbH (Germany), Y-mAbs Therapeutics Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel) and among others.

Scope of the Monoclonal Antibody Therapeutics Industry

Report Metric

Details

Market Revenue Size in 2024

$252.6 billion

Projected Revenue Size by 2029

$497.5 billion

Industry Growth Rate

Poised to Grow at a CAGR of 14.5%

Market Driver

Advancements in Biotechnology and Genetic Engineering

Market Opportunity

Expansion into new therapeutic areas

This report categorizes the monoclonal antibody therapeutics market to forecast revenue and analyze trends in each of the following submarkets:

By Production Method
  • In-Vitro
  • In-Vivo
By Sources
  • Human
  • Humanized
  • Chimeric
  • Other Sources
By Route of Administration
  • Intravenous
  • Subcutaneous
  • Other Route of Administration
By Therapy Area
  • Autoimmune & Inflammatory Disorders
  • Oncology
  • Hematology
  • Ophthalmology
  • Other Therapy Areas
By End User
  • Hospitals
  • Long-term Care Facilities
  • Other End Users
By Region
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Turkey
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • South Korea
    • Indonesia
    • Malaysia
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Rest of Latin America (RoLATAM)
  • Middle East & Africa
    • Middle East
      • GCC Countries
        • Saudi Arabia (KSA)
        • United Arab Emirates (UAE)
        • Rest of GCC Countries
      • Rest of Middle East (RoME)
  • Africa

Recent Developments of Monoclonal Antibody Therapeutics Industry:

  • In January 2024, UCB Inc., received U.S. FDA approval for RYSTIGGO (rozanolixizumab-noli) or the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
  • In August 2023, Regeneron Pharmaceuticals, Inc. received U.S. FDA approval Veopoz (pozelimab-bbfg) for the treatment of adult and pediatric patients 1 year of age and older with CHAPLE disease, also known as CD55-deficient protein-losing enteropathy.
  • In August 2023, Pfizer received U.S. FDA accelerated approval for ELREXFIO (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy.
  • In August 2023, Janssen Pharmaceutical Companies of Johnson & Johnson received U.S. FDA accelerated approval for TALVEY (talquetamab-tgvs), a first-in-class bispecific antibody for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy,

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 29)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
           1.3.3 CURRENCY CONSIDERED
    1.4 RESEARCH LIMITATIONS 
    1.5 STAKEHOLDERS 
    1.6 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 33)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 3 MONOCLONAL ANTIBODY THERAPEUTICS: MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2023
          FIGURE 4 MONOCLONAL ANTIBODY THERAPEUTICS: MARKET SIZE ESTIMATION (PRODUCT-BASED ANALYSIS), 2023
          FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
          FIGURE 6 ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE AG: REVENUE SHARE ANALYSIS, 2023
           2.2.1 INSIGHTS FROM PRIMARIES
                    FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
           2.2.2 SEGMENT ASSESSMENT (BY PRODUCTION METHOD, SOURCE, ROUTE OF ADMINISTRATION, THERAPY AREA, AND END USER)
                    FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    2.3 GROWTH RATE ASSUMPTIONS 
          FIGURE 9 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: CAGR PROJECTIONS, 2024–2029
          FIGURE 10 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 11 DATA TRIANGULATION METHODOLOGY
    2.5 STUDY ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 RECESSION IMPACT ANALYSIS 
 
3 EXECUTIVE SUMMARY (Page No. - 46)
    FIGURE 12 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2024 VS. 2029 (USD MILLION)
    FIGURE 13 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY, BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION)
    FIGURE 14 MARKET, BY THERAPY TYPE, 2024 VS. 2029 (USD MILLION)
    FIGURE 15 MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
    FIGURE 16 GEOGRAPHICAL SNAPSHOT OF MARKET
 
4 PREMIUM INSIGHTS (Page No. - 50)
    4.1 MARKET OVERVIEW 
          FIGURE 17 ADVANCEMENTS IN BIOTECHNOLOGY AND GENETIC ENGINEERING TO DRIVE MARKET DURING FORECAST PERIOD
    4.2 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY, BY PRODUCTION METHOD (2023) 
          FIGURE 18 IN-VITRO PRODUCTION METHOD ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
    4.3 MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION) 
          FIGURE 19 HUMAN SOURCE SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
    4.4 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 20 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 53)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 21 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Advancements in biotechnology and genetic engineering
                    5.2.1.2 Increasing demand for personalized medicine
                    5.2.1.3 Growing product pipeline of mAb therapeutics
                                FIGURE 22 NUMBER OF ANTIBODY THERAPEUTICS GRANTED FIRST APPROVAL IN US/EU (2012−2023)
           5.2.2 RESTRAINTS
                    5.2.2.1 Stringent regulatory approval process
                    5.2.2.2 High cost of mAb treatments
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Innovative therapeutic indications
                    5.2.3.2 Rising technological advancements in antibody engineering
           5.2.4 CHALLENGES
                    5.2.4.1 Rising development & production costs
    5.3 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 1 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: PORTER’S FIVE FORCES ANALYSIS
           5.3.1 THREAT OF NEW ENTRANTS
           5.3.2 THREAT OF SUBSTITUTES
           5.3.3 BARGAINING POWER OF SUPPLIERS
           5.3.4 BARGAINING POWER OF BUYERS
           5.3.5 INTENSITY OF COMPETITIVE RIVALRY
    5.4 TECHNOLOGY ANALYSIS 
           5.4.1 CONVENTIONAL PRODUCTION OF MABS
           5.4.2 TECHNOLOGICAL ADVANCEMENTS FOR MABS
                    TABLE 2 MARKET: TECHNOLOGY COMPARISON
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 23 MARKET: VALUE CHAIN
    5.6 PATENT ANALYSIS 
           5.6.1 METHODOLOGY
           5.6.2 PATENTS FILED BY DOCUMENT TYPE, 2014–2023
                    TABLE 3 PATENTS FILED, 2014–2023
           5.6.3 INNOVATION AND PATENT APPLICATIONS
                    FIGURE 24 TOTAL NUMBER OF PATENTS GRANTED, 2014–2023
           5.6.4 TOP APPLICANTS
                    FIGURE 25 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2023
                    FIGURE 26 REGIONAL ANALYSIS OF PATENTS GRANTED, 2014–2023
                    TABLE 4 TOP 10 PATENT OWNERS IN MARKET, 2013–2023
                    TABLE 5 PATENTS IN MARKET, 2023−2024
    5.7 KEY CONFERENCES & EVENTS 
          TABLE 6 MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2024–2025)
    5.8 INVESTMENT AND FUNDING SCENARIO 
    5.9 PIPELINE ANALYSIS 
          TABLE 7 MONOCLONAL ANTIBODY THERAPEUTICS IN CLINICAL PIPELINE
    5.10 SUPPLY CHAIN ANALYSIS 
           FIGURE 27 MARKET: SUPPLY CHAIN ANALYSIS
    5.11 ECOSYSTEM ANALYSIS 
           FIGURE 28 MONOCLONAL ANTIBODY THERAPEUTICS ECOSYSTEM
           5.11.1 MONOCLONAL ANTIBODY THERAPEUTIC VENDORS
                     TABLE 8 MONOCLONAL ANTIBODY THERAPEUTIC VENDORS
           5.11.2 END USERS OF MONOCLONAL ANTIBODY THERAPEUTICS
                     TABLE 9 MONOCLONAL ANTIBODY THERAPEUTIC END USERS
           5.11.3 REGULATORY BODIES FOR MONOCLONAL ANTIBODY THERAPEUTICS
                     TABLE 10 MONOCLONAL ANTIBODY THERAPEUTIC REGULATORY BODIES
    5.12 REGULATORY LANDSCAPE 
           5.12.1 REGULATORY ANALYSIS
           5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.13 PRICING ANALYSIS 
           5.13.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS
                     TABLE 15 AVERAGE SELLING PRICE OF MONOCLONAL ANTIBODY THERAPEUTICS IN US
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           FIGURE 29 TECHNOLOGICAL ADVANCEMENTS IN MONOCLONAL ANTIBODY PRODUCTION TO DRIVE MARKET GROWTH
    5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.15.1 KEY STAKEHOLDERS ON BUYING PROCESS
                     FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MABS AMONG TOP TWO END USERS
                     TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP TWO END USERS
           5.15.2 BUYING CRITERIA FOR MONOCLONAL ANTIBODY THERAPEUTICS
                     FIGURE 31 KEY BUYING CRITERIA FOR HOSPITALS AND LONG-TERM CARE FACILITIES
                     TABLE 17 KEY BUYING CRITERIA FOR TOP TWO END USERS
 
6 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD (Page No. - 88)
    6.1 INTRODUCTION 
          TABLE 18 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
    6.2 IN-VITRO PRODUCTION 
           6.2.1 HIGH SCALABILITY AND COST EFFICIENCY TO PROPEL MARKET
                    TABLE 19 MARKET FOR IN-VITRO PRODUCTION, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 20 NORTH AMERICA: MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 21 EUROPE: MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 22 ASIA PACIFIC: MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 23 LATIN AMERICA: MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 24 MIDDLE EAST: MARKET FOR IN-VITRO PRODUCTION, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 25 GCC COUNTRIES: MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
    6.3 IN-VIVO PRODUCTION 
           6.3.1 MINIMAL SIDE-EFFECTS TO SUPPORT MARKET GROWTH
                    TABLE 26 MARKET FOR IN-VIVO PRODUCTION, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 27 NORTH AMERICA: MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 28 EUROPE: MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 29 ASIA PACIFIC: MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 30 LATIN AMERICA: MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 31 MIDDLE EAST: MARKET FOR IN-VIVO PRODUCTION, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 32 GCC COUNTRIES: MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
 
7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 97)
    7.1 INTRODUCTION 
          TABLE 33 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
    7.2 INTRAVENOUS ROUTE OF ADMINISTRATION 
           7.2.1 DIRECT DELIVERY OF THERAPEUTIC DOSAGE FOR MULTIPLE INDICATIONS TO DRIVE MARKET
                    TABLE 34 MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 35 NORTH AMERICA: MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 36 EUROPE: MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 37 ASIA PACIFIC: MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 38 LATIN AMERICA: MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 39 MIDDLE EAST: MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 40 GCC COUNTRIES: MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
    7.3 SUBCUTANEOUS ROUTE OF ADMINISTRATION 
           7.3.1 ENHANCED PATIENT ADHERENCE AND LOW HEALTHCARE COSTS TO DRIVE MARKET
                    TABLE 41 MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 42 NORTH AMERICA: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 43 EUROPE: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 44 ASIA PACIFIC: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 45 LATIN AMERICA: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 46 MIDDLE EAST: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022−2029 USD MILLION)
                    TABLE 47 GCC COUNTRIES: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
    7.4 OTHER ROUTES OF ADMINISTRATION 
          TABLE 48 MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION)
          TABLE 49 NORTH AMERICA: MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 50 EUROPE: MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 51 ASIA PACIFIC: MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 52 LATIN AMERICA: MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 53 MIDDLE EAST: MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION)
          TABLE 54 GCC COUNTRIES: MARKET FOR OTHER ROUTESC OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
 
8 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE (Page No. - 110)
    8.1 INTRODUCTION 
          TABLE 55 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY, BY SOURCE, 2022–2029 (USD MILLION)
    8.2 HUMAN SOURCE 
           8.2.1 REDUCED IMMUNOGENICITY AND IMPROVED EFFICACY TO PROPEL MARKET
                    TABLE 56 MARKET FOR HUMAN SOURCE, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 57 NORTH AMERICA: MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 58 EUROPE: MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 59 ASIA PACIFIC: MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 60 LATIN AMERICA: MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 61 MIDDLE EAST: MARKET FOR HUMAN SOURCE, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 62 GCC COUNTRIES: MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
    8.3 HUMANIZED SOURCE 
           8.3.1 ABILITY TO ADJUST SPECIFICITY AND BIOLOGICAL FUNCTIONS TO DRIVE MARKET
                    TABLE 63 MARKET FOR HUMANIZED SOURCE, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 64 NORTH AMERICA: MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 65 EUROPE: MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 66 ASIA PACIFIC: MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 67 LATIN AMERICA: MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 68 MIDDLE EAST: MARKET FOR HUMANIZED SOURCE, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 69 GCC COUNTRIES: MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
    8.4 CHIMERIC SOURCE 
           8.4.1 UTILIZATION OF GENETIC ENGINEERING TECHNIQUES FOR MINIMIZED IMMUNOGENIC RESPONSES TO FUEL MARKET
                    TABLE 70 MARKET FOR CHIMERIC SOURCE, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 71 NORTH AMERICA: MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 72 EUROPE: MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 73 ASIA PACIFIC: MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 74 LATIN AMERICA: MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 75 MIDDLE EAST: MARKET FOR CHIMERIC SOURCE, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 76 GCC COUNTRIES: MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
    8.5 OTHER SOURCES 
          TABLE 77 MARKET FOR OTHER SOURCES, BY REGION, 2022–2029 (USD MILLION)
          TABLE 78 NORTH AMERICA: MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 79 EUROPE: MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 80 ASIA PACIFIC: MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 81 LATIN AMERICA: MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 82 MIDDLE EAST: MARKET FOR OTHER SOURCES, BY REGION, 2022–2029 (USD MILLION)
          TABLE 83 GCC COUNTRIES: MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)
 
9 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA (Page No. - 126)
    9.1 INTRODUCTION 
          TABLE 84 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY, BY THERAPY AREA, 2022–2029 (USD MILLION)
    9.2 INFLAMMATORY & AUTOIMMUNE DISORDERS 
           9.2.1 RISING DEMAND FOR TARGETED THERAPEUTICS TO DRIVE MARKET
                    TABLE 85 MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 86 NORTH AMERICA: MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 87 EUROPE: MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 88 ASIA PACIFIC: MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 89 LATIN AMERICA: THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 90 MIDDLE EAST: MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 91 GCC COUNTRIES: MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
    9.3 ONCOLOGY 
           9.3.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO PROPEL MARKET
                    TABLE 92 MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 93 NORTH AMERICA: MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 94 EUROPE: MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 95 ASIA PACIFIC: MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 96 LATIN AMERICA: MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 97 MIDDLE EAST: MARKET FOR CANCER, BY REGION, 2022−2029 (USD MILLION)
                    TABLE 98 GCC COUNTRIES: MARKET FOR CANCER, BY COUNTRY, 2022−2029 (USD MILLION)
    9.4 HEMATOLOGY 
           9.4.1 RISING INCIDENCE OF THROMBOTIC DISORDERS TO SUPPORT MARKET GROWTH
                    TABLE 99 MARKET FOR HEMATOLOGY, BY REGION, 2022−2029 (USD MILLION)
                    TABLE 100 NORTH AMERICA: MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 101 EUROPE: MARKET FOR HEMATOLOGY, BY COUNTRY, 2022−2029 (USD MILLION)
                    TABLE 102 ASIA PACIFIC: MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 103 LATIN AMERICA: MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 104 MIDDLE EAST: MARKET FOR HEMATOLOGY, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 105 GCC COUNTRIES: MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
    9.5 OPHTHALMOLOGY 
           9.5.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION TO BOOST DEMAND
                    TABLE 106 MARKET FOR OPHTHALMOLOGY, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 107 NORTH AMERICA: MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 108 EUROPE: MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 109 ASIA PACIFIC: MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 110 LATIN AMERICA: MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 111 MIDDLE EAST: MARKET FOR OPHTHALMOLOGY, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 112 GCC COUNTRIES: MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
    9.6 OTHER THERAPY AREAS 
          TABLE 113 MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2029 (USD MILLION)
          TABLE 114 NORTH AMERICA: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 115 EUROPE: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 116 ASIA PACIFIC: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 117 LATIN AMERICA: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 118 MIDDLE EAST: MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2029 (USD MILLION)
          TABLE 119 GCC COUNTRIES: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
 
10 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER (Page No. - 146)
     10.1 INTRODUCTION 
             TABLE 120 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY, BY END USER, 2022–2029 (USD MILLION)
     10.2 HOSPITALS 
             10.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET
                        TABLE 121 MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION)
                        TABLE 122 NORTH AMERICA: MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 123 EUROPE: MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 124 ASIA PACIFIC: MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 125 LATIN AMERICA: MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 126 MIDDLE EAST: MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION)
                        TABLE 127 GCC COUNTRIES: MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
     10.3 LONG-TERM CARE FACILITIES 
             10.3.1 SPECIALIZED CARE AND CONTINUOUS MONITORING ADVANTAGES TO DRIVE MARKET
                        TABLE 128 MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION)
                        TABLE 129 NORTH AMERICA: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 130 EUROPE: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 131 ASIA PACIFIC: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 132 LATIN AMERICA: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 133 MIDDLE EAST: MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION)
                        TABLE 134 GCC COUNTRIES: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
     10.4 OTHER END USERS 
             TABLE 135 MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
             TABLE 136 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
             TABLE 137 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
             TABLE 138 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
             TABLE 139 LATIN AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
             TABLE 140 MIDDLE EAST: MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
             TABLE 141 GCC COUNTRIES: MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
 
11 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION (Page No. - 158)
     11.1 INTRODUCTION 
             TABLE 142 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY, BY REGION, 2022–2029 (USD MILLION)
     11.2 NORTH AMERICA 
             FIGURE 32 NORTH AMERICA: MARKET SNAPSHOT
             TABLE 143 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
             TABLE 144 NORTH AMERICA: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
             TABLE 145 NORTH AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
             TABLE 146 NORTH AMERICA: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
             TABLE 147 NORTH AMERICA: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
             TABLE 148 NORTH AMERICA: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.2.1 NORTH AMERICA: RECESSION IMPACT
             11.2.2 US
                        11.2.2.1 Rising regulatory approvals for product commercialization to propel market
                                      TABLE 149 PRODUCT APPROVALS FOR MAB THERAPEUTICS BY US FDA
                                      TABLE 150 US: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                      TABLE 151 US: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                      TABLE 152 US: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 153 US: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                      TABLE 154 US: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.2.3 CANADA
                        11.2.3.1 Rising investments in antibody research to support market growth
                                      TABLE 155 CANADA: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                      TABLE 156 CANADA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                      TABLE 157 CANADA: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 158 CANADA: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                      TABLE 159 CANADA: MARKET, BY END USER, 2022–2029 (USD MILLION)
     11.3 EUROPE 
             FIGURE 33 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET SNAPSHOT
             TABLE 160 EUROPE: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
             TABLE 161 EUROPE: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
             TABLE 162 EUROPE: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
             TABLE 163 EUROPE: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
             TABLE 164 EUROPE: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
             TABLE 165 EUROPE: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.3.1 EUROPE: RECESSION IMPACT
             11.3.2 GERMANY
                        11.3.2.1 Rising number of clinical trials for mAb therapeutics to drive market
                                      TABLE 166 GERMANY: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                      TABLE 167 GERMANY: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                      TABLE 168 GERMANY: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 169 GERMANY: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                      TABLE 170 GERMANY: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.3.3 UK
                        11.3.3.1 Increasing R&D initiatives by pharmaceutical & biotechnology companies to support market growth
                                      TABLE 171 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
                                      TABLE 172 UK: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                      TABLE 173 UK: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                      TABLE 174 UK: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 175 UK: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                      TABLE 176 UK: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.3.4 FRANCE
                        11.3.4.1 Favorable reimbursement policies for therapeutic treatments to propel market
                                      TABLE 177 FRANCE: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                      TABLE 178 FRANCE: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                      TABLE 179 FRANCE: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 180 FRANCE: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                      TABLE 181 FRANCE: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.3.5 ITALY
                        11.3.5.1 Growth in life sciences industry to boost demand
                                      TABLE 182 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                      TABLE 183 ITALY: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                      TABLE 184 ITALY: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 185 ITALY: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                      TABLE 186 ITALY: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.3.6 SPAIN
                        11.3.6.1 Growing focus on research for biomaterial development to drive market
                                      TABLE 187 SPAIN: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                      TABLE 188 SPAIN: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                      TABLE 189 SPAIN: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 190 SPAIN: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                      TABLE 191 SPAIN: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.3.7 TURKEY
                        11.3.7.1 Rising investments in R&D for healthcare infrastructure to support market growth
                                      TABLE 192 TURKEY: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                      TABLE 193 TURKEY: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                      TABLE 194 TURKEY: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 195 TURKEY: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                      TABLE 196 TURKEY: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.3.8 REST OF EUROPE
                        TABLE 197 REST OF EUROPE: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                        TABLE 198 REST OF EUROPE: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                        TABLE 199 REST OF EUROPE: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 200 REST OF EUROPE: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                        TABLE 201 REST OF EUROPE: MARKET, BY END USER, 2022–2029 (USD MILLION)
     11.4 ASIA PACIFIC 
             TABLE 202 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
             TABLE 203 ASIA PACIFIC: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
             TABLE 204 ASIA PACIFIC: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
             TABLE 205 ASIA PACIFIC: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
             TABLE 206 ASIA PACIFIC: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
             TABLE 207 ASIA PACIFIC: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.4.1 ASIA PACIFIC: RECESSION IMPACT
             11.4.2 CHINA
                        11.4.2.1 Growing preference for precision medicines to propel market
                                      TABLE 208 CHINA: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                      TABLE 209 CHINA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                      TABLE 210 CHINA: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 211 CHINA: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                      TABLE 212 CHINA: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.4.3 JAPAN
                        11.4.3.1 Availability of healthcare insurance and favorable regulatory environment to propel market
                                      TABLE 213 JAPAN: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                      TABLE 214 JAPAN: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                      TABLE 215 JAPAN: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 216 JAPAN: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                      TABLE 217 JAPAN: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.4.4 INDIA
                        11.4.4.1 Increasing incidence of chronic diseases and high growth in pharma R&D to fuel market
                                      TABLE 218 INDIA: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                      TABLE 219 INDIA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                      TABLE 220 INDIA: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 221 INDIA: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                      TABLE 222 INDIA: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.4.5 SOUTH KOREA
                        11.4.5.1 Strategic initiatives by key players to support market growth
                                      TABLE 223 SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                      TABLE 224 SOUTH KOREA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                      TABLE 225 SOUTH KOREA: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 226 SOUTH KOREA: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                      TABLE 227 SOUTH KOREA: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.4.6 INDONESIA
                        11.4.6.1 Funding initiatives and key product launches to support market growth
                                      TABLE 228 INDONESIA: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                      TABLE 229 INDONESIA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                      TABLE 230 INDONESIA: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 231 INDONESIA: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                      TABLE 232 INDONESIA: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.4.7 MALAYSIA
                        11.4.7.1 Increasing focus on government-funded initiatives for management of chronic ailments to support market growth
                                      TABLE 233 MALAYSIA: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                      TABLE 234 MALAYSIA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                      TABLE 235 MALAYSIA: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 236 MALAYSIA: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                      TABLE 237 MALAYSIA: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.4.8 REST OF ASIA PACIFIC
                        TABLE 238 REST OF ASIA PACIFIC: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                        TABLE 239 REST OF ASIA PACIFIC: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                        TABLE 240 REST OF ASIA PACIFIC: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 241 REST OF ASIA PACIFIC: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                        TABLE 242 REST OF ASIA PACIFIC: MARKET, BY END USER, 2022–2029 (USD MILLION)
     11.5 LATIN AMERICA 
             TABLE 243 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
             TABLE 244 LATIN AMERICA: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
             TABLE 245 LATIN AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
             TABLE 246 LATIN AMERICA: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
             TABLE 247 LATIN AMERICA: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
             TABLE 248 LATIN AMERICA: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.5.1 LATIN AMERICA: RECESSION IMPACT
             11.5.2 BRAZIL
                        11.5.2.1 Increasing incidence of chronic & infectious diseases to drive market
                                      TABLE 249 BRAZIL: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                      TABLE 250 BRAZIL: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                      TABLE 251 BRAZIL: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 252 BRAZIL: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                      TABLE 253 BRAZIL: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.5.3 REST OF LATIN AMERICA
                        TABLE 254 REST OF LATIN AMERICA: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                        TABLE 255 REST OF LATIN AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                        TABLE 256 REST OF LATIN AMERICA: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 257 REST OF LATIN AMERICA: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                        TABLE 258 REST OF LATIN AMERICA: MARKET, BY END USER, 2022–2029 (USD MILLION)
     11.6 MIDDLE EAST 
             TABLE 259 MIDDLE EAST: MARKET, BY REGION, 2022–2029 (USD MILLION)
             TABLE 260 MIDDLE EAST: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
             TABLE 261 MIDDLE EAST: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
             TABLE 262 MIDDLE EAST: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
             TABLE 263 MIDDLE EAST: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
             TABLE 264 MIDDLE EAST: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.6.1 MIDDLE EAST: RECESSION IMPACT
             11.6.2 GCC COUNTRIES
                        TABLE 265 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 266 GCC COUNTRIES: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                        TABLE 267 GCC COUNTRIES: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                        TABLE 268 GCC COUNTRIES: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 269 GCC COUNTRIES: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                        TABLE 270 GCC COUNTRIES: MARKET, BY END USER, 2022–2029 (USD MILLION)
                        11.6.2.1 Saudi Arabia
                                     11.6.2.1.1 Rising prevalence of CVD to support market growth
                                                      TABLE 271 SAUDI ARABIA: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                                      TABLE 272 SAUDI ARABIA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                                      TABLE 273 SAUDI ARABIA: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                                      TABLE 274 SAUDI ARABIA: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                                      TABLE 275 SAUDI ARABIA: MARKET, BY END USER, 2022–2029 (USD MILLION)
                        11.6.2.2 United Arab Emirates
                                     11.6.2.2.1 Rising prevalence of diabetes to boost demand
                                                      TABLE 276 UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                                      TABLE 277 UNITED ARAB EMIRATES: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                                      TABLE 278 UNITED ARAB EMIRATES: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                                      TABLE 279 UNITED ARAB EMIRATES: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                                      TABLE 280 UNITED ARAB EMIRATES: MARKET, BY END USER, 2022–2029 (USD MILLION)
                        11.6.2.3 Other GCC countries
                                      TABLE 281 OTHER GCC COUNTRIES: MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                                      TABLE 282 OTHER GCC COUNTRIES: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                                      TABLE 283 OTHER GCC COUNTRIES: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 284 OTHER GCC COUNTRIES: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                                      TABLE 285 OTHER GCC COUNTRIES: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.6.3 REST OF MIDDLE EAST
                        TABLE 286 REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                        TABLE 287 REST OF MIDDLE EAST: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                        TABLE 288 REST OF MIDDLE EAST: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 289 REST OF MIDDLE EAST: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                        TABLE 290 REST OF MIDDLE EAST: MARKET, BY END USER, 2022–2029 (USD MILLION)
     11.7 AFRICA 
             11.7.1 HIGH INVESTMENTS IN HEALTHCARE R&D TO SUPPORT MARKET GROWTH
                        TABLE 291 AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
                        TABLE 292 AFRICA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
                        TABLE 293 AFRICA: MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 294 AFRICA: MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
                        TABLE 295 AFRICA: MARKET, BY END USER, 2022–2029 (USD MILLION)
             11.7.2 AFRICA: RECESSION IMPACT
 
12 COMPETITIVE LANDSCAPE (Page No. - 238)
     12.1 INTRODUCTION 
     12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
             FIGURE 34 STRATEGIES ADOPTED BY KEY PLAYERS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET
     12.3 REVENUE SHARE ANALYSIS 
             FIGURE 35 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2020−2023)
     12.4 MARKET SHARE ANALYSIS 
             FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
             TABLE 296 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: DEGREE OF COMPETITION
     12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 37 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2023)
             12.5.5 COMPANY FOOTPRINT
                        FIGURE 38 COMPANY FOOTPRINT (15 COMPANIES)
                        12.5.5.1 Type footprint
                                     TABLE 297 TYPE FOOTPRINT (15 COMPANIES)
                        12.5.5.2 Regional footprint
                                     TABLE 298 REGIONAL FOOTPRINT (15 COMPANIES)
     12.6 COMPANY EVALUATION MATRIX: STARTUP/SME PLAYERS 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 DYNAMIC COMPANIES
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 STARTING BLOCKS
                        FIGURE 39 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2023)
     12.7 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 
             TABLE 299 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: DETAILED LIST OF KEY STARTUP/SME PLAYERS
             TABLE 300 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
     12.8 VALUATION AND FINANCIAL METRICS OF MONOCLONAL ANTIBODY THERAPEUTIC VENDORS 
             FIGURE 40 EV/EBITDA OF KEY VENDORS
             FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
     12.9 BRAND/PRODUCT COMPARATIVE ANALYSIS 
             12.9.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND SOURCE
                        FIGURE 42 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND SOURCE
                        12.9.1.1 F. Hoffmann-La Roche Ltd.
                        12.9.1.2 Johnson & Johnson Services, Inc.
                        12.9.1.3 Merck & Co., Inc.
                        12.9.1.4 AbbVie inc.
                        12.9.1.5 Sanofi
             12.9.2 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND HUMAN SOURCE
                        FIGURE 43 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND HUMAN SOURCE
                        12.9.2.1 AstraZeneca
                        12.9.2.2 Bristol Myers Squibb Company
                        12.9.2.3 Novartis AG
     12.10 COMPETITIVE SCENARIO 
             12.10.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 301 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: PRODUCT LAUNCHES & APPROVALS (JANUARY 2021−JANUARY 2024)
             12.10.2 DEALS
                        TABLE 302 MONOCLONAL ANTIBODY THERAPEUTICS INDUSTRY: DEALS (JANUARY 2021−JANUARY 2024)
             12.10.3 OTHER DEVELOPMENTS
                        TABLE 303 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: OTHER DEVELOPMENTS (JANUARY 2021−JANUARY 2024)
 
13 COMPANY PROFILES (Page No. - 258)
(Business overview, Products/Services offered, Recent developments & MnM View)*
     13.1 KEY PLAYERS 
             13.1.1 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 304 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
                        FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
                        TABLE 305 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
                        TABLE 306 F. HOFFMAN LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS
                        TABLE 307 F. HOFFMAN LA ROCHE LTD.: DEALS
             13.1.2 JOHNSON & JOHNSON SERVICES, INC.
                        TABLE 308 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
                        FIGURE 45 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2022)
                        TABLE 309 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS/SERVICES OFFERED
                        TABLE 310 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS
             13.1.3 MERCK & CO., INC.
                        TABLE 311 MERCK & CO., INC.: COMPANY OVERVIEW
                        FIGURE 46 MERCK & CO., INC COMPANY SNAPSHOT (2022)
                        TABLE 312 MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED
                        TABLE 313 MERCK & CO., INC.: PRODUCT APPROVALS
             13.1.4 ABBVIE INC.
                        TABLE 314 ABBVIE INC.: COMPANY OVERVIEW
                        FIGURE 47 ABBVIE INC.: COMPANY SNAPSHOT (2022)
                        TABLE 315 ABBVIE INC.: PRODUCTS /SERVICES OFFERED
                        TABLE 316 ABBVIE INC.: PRODUCT APPROVALS
                        TABLE 317 ABBVIE INC.: DEALS
             13.1.5 BRISTOL-MYERS SQUIBB COMPANY
                        TABLE 318 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
                        FIGURE 48 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2022)
                        TABLE 319 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES OFFERED
                        TABLE 320 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS
                        TABLE 321 BRISTOL-MYERS SQUIBB COMPANY: DEALS
                        TABLE 322 BRISTOL-MYERS SQUIBB COMPANY: OTHER DEVELOPMENTS
             13.1.6 ASTRAZENECA
                        TABLE 323 ASTRAZENECA: COMPANY OVERVIEW
                        FIGURE 49 ASTRAZENECA: COMPANY SNAPSHOT (2022)
                        TABLE 324 ASTRAZENECA: PRODUCTS/SERVICES OFFERED
                        TABLE 325 ASTRAZENECA: PRODUCT APPROVALS
                        TABLE 326 ASTRAZENECA: DEALS
             13.1.7 SANOFI
                        TABLE 327 SANOFI: COMPANY OVERVIEW
                        FIGURE 50 SANOFI: COMPANY SNAPSHOT (2022)
                        TABLE 328 SANOFI: PRODUCTS/SERVICES OFFERED
                        TABLE 329 SANOFI: PRODUCT APPROVALS
                        TABLE 330 SANOFI: DEALS
             13.1.8 NOVARTIS AG
                        TABLE 331 NOVARTIS AG: COMPANY OVERVIEW
                        FIGURE 51 NOVARTIS AG: COMPANY SNAPSHOT (2022)
                        TABLE 332 NOVARTIS AG: PRODUCTS/SERVICES OFFERED
                        TABLE 333 NOVARTIS AG: PRODUCT APPROVALS
                        TABLE 334 NOVARTIS AG: DEALS
                        TABLE 335 NOVARTIS AG: OTHER DEVELOPMENTS
             13.1.9 AMGEN INC.
                        TABLE 336 AMGEN INC.: COMPANY OVERVIEW
                        FIGURE 52 AMGEN INC.: COMPANY SNAPSHOT (2022)
                        TABLE 337 AMGEN INC.: PRODUCTS/SERVICES OFFERED
                        TABLE 338 AMGEN INC.: PRODUCT APPROVALS
                        TABLE 339 AMGEN INC.: DEALS
                        TABLE 340 AMGEN INC.: EXPANSIONS
             13.1.10 TAKEDA PHARMACEUTICAL COMPANY LIMITED
                        TABLE 341 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
                        FIGURE 53 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
                        TABLE 342 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS/SERVICES OFFERED
                        TABLE 343 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS
             13.1.11 GSK PLC.
                        TABLE 344 GSK PLC.: COMPANY OVERVIEW
                        FIGURE 54 GSK PLC.: COMPANY SNAPSHOT (2022)
                        TABLE 345 GSK PLC.: PRODUCTS/SERVICES OFFERED
                        TABLE 346 GSK PLC.: PRODUCT APPROVALS
                        TABLE 347 GSK PLC.: DEALS
                        TABLE 348 GSK PLC.: OTHER DEVELOPMENTS
             13.1.12 ELI LILLY AND COMPANY
                        TABLE 349 ELI LILLY AND COMPANY: COMPANY OVERVIEW
                        FIGURE 55 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022)
                        TABLE 350 ELI LILLY AND COMPANY: PRODUCTS/SERVICES OFFERED
                        TABLE 351 ELI LILLY AND COMPANY: PRODUCT APPROVALS
                        TABLE 352 ELI LILLY AND COMPANY: DEALS
                        TABLE 353 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS
             13.1.13 REGENERON PHARMACEUTICALS INC.
                        TABLE 354 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW
                        FIGURE 56 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2022)
                        TABLE 355 REGENERON PHARMACEUTICALS INC.: PRODUCTS/SERVICES OFFERED
                        TABLE 356 REGENERON PHARMACEUTICALS INC.: PRODUCT APPROVALS
                        TABLE 357 REGENERON PHARMACEUTICALS INC.: DEALS
             13.1.14 BIOGEN
                        TABLE 358 BIOGEN: COMPANY OVERVIEW
                        FIGURE 57 BIOGEN: COMPANY SNAPSHOT (2022)
                        TABLE 359 BIOGEN: PRODUCTS/SERVICES OFFERED
                        TABLE 360 BIOGEN: PRODUCT APPROVALS
                        TABLE 361 BIOGEN: DEALS
             13.1.15 UCB S.A.
                        TABLE 362 UCB S.A.: COMPANY OVERVIEW
                        FIGURE 58 UCB S.A.: COMPANY SNAPSHOT (2022)
                        TABLE 363 UCB S.A.: PRODUCTS/SERVICES OFFERED
                        TABLE 364 UCB S.A.: DEALS
                        TABLE 365 UCB S.A.: PRODUCT APPROVALS
     13.2 OTHER PLAYERS 
             13.2.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
             13.2.2 Y-MABS THERAPEUTICS, INC.
             13.2.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
             13.2.4 MERCK KGAA
             13.2.5 KYOWA KIRIN CO., LTD.
             13.2.6 SWEDISH ORPHAN BIOVITRUM AB
             13.2.7 UNITED THERAPEUTICS CORPORATION
             13.2.8 THERATECHNOLOGIES INC.
             13.2.9 INCYTE
             13.2.10 SUN PHARMACEUTICAL INDUSTRIES, INC.
 
*Details on Business overview, Products/Services offered, Recent developments & MnM View might not be captured in case of unlisted companies.
 
14 APPENDIX (Page No. - 343)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATIONS OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global monoclonal antibody therapeutics market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the monoclonal antibody therapeutics market. The secondary sources used for this study include U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Centers for Disease Control and Prevention (CDC), The Antibody Society, World Health Organization (WHO), National Institutes of Health (NIH), European Centre for Disease Prevention and Control (ECDC), mAbs (Monoclonal Antibodies in Immunodiagnosis and Immunotherapy), Antibody Engineering & Therapeutics (AET), Therapeutic Antibodies, Antibody Technology Journal (ATJ), U.S. Department of Health and Human Services, National Institutes of Health, National Library of Medicine, National Center for Biotechnology Information, China National Medical Products Administration (NMPA), Australian Therapeutic Goods Administration (TGA), Pharmaceuticals and Medical Devices Agency (PMDA), Brazilian Health Regulatory Agency (ANVISA), International Trade Centre, Annual Reports, SEC Filings, Investor Presentations, Research Journals, Press Releases, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global monoclonal antibody therapeutics market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side (personnel from Hospitals and Clinics, Patients, Pharmaceutical Companies, Long Term Care Centers) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, from Tier 1 and Tier 2 companies engaged in offering products) across five major regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

Approximately 70% of primary interviews were conducted with supply side representatives, while demand side participants accounted for the remaining share. The primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Monoclonal Antibody (mABs) Therapeutics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the monoclonal antibody therapeutics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Bottom-up Approach

  • The key players in the industry and market have been identified through extensive secondary research.
  • The revenues generated from the monoclonal antibody therapeutics market business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Monoclonal Antibody (mABs) Therapeutics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Top-down Approach

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

Monoclonal Antibody (mABs) Therapeutics Market Size, and Share

Data Triangulation

To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

The monoclonal antibody therapeutics market comprises drugs developed from identical immune cells that specifically target a single antigen, commonly used to treat various diseases like cancer, autoimmune disorders, and infectious diseases. These drugs are produced in large quantities and have a significant impact on the pharmaceutical industry due to their specificity and efficacy.

Stakeholders

  • Pharmaceutical & Biotechnology Companies
  • Life Sciences Companies
  • Academic & Research Institutes
  • Government Institutes
  • Contract Research Organizations (CROs)
  • Hospitals and Specialities Clinics
  • Long-term Care Center
  • Third-party Suppliers, Direct Suppliers, Distributors, and Channel Partners
  • Venture Capitalists and Investors

Report Objectives

  • To define, describe, and forecast the monoclonal antibody therapeutics market based on production method, sources, route of administration, therapy area, end user, and region.
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges).
  • To analyze micromarkets for individual growth trends, prospects, and contributions to the overall monoclonal antibody therapeutics market.
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders.
  • To forecast the market size of the segments concerning six regions, namely: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.
  • To profile the key players and analyze their market shares and core competencies
  • To track and analyze competitive developments, such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations.
  • To benchmark players within the market using the proprietary “Competitive Leadership Mapping” framework, which analyzes market players on various parameters within the broad categories of business & product excellence strategy.  

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographical Analysis

  • Further breakdown of the Rest of Europe monoclonal antibody therapeutics market, by country
  • Further breakdown of the Rest of Asia Pacific monoclonal antibody therapeutics market, by country
  • Further breakdown of the Rest of Latin America monoclonal antibody therapeutics market, by country
  • Further breakdown of the Rest of Middle East monoclonal antibody therapeutics market, by country
  • Further breakdown of the Rest of GCC Countries monoclonal antibody therapeutics market, by country

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

Segment Analysis

  • Further breakdown of the other technologies and other therapeutic area into subsegments
  • Cross-segment analysis
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization
Report Code
PH 8974
Published ON
Mar, 2024
REQUEST FREE SAMPLE REPORT
Choose License Type
BUY NOW
Inquire Before Buying
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Monoclonal Antibody Therapeutics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback